Evaluation of the Effectiveness of Extending the "Passerelle" System for Prescribing Adapted Physical Activity to Patients With Type 2 Diabetes in Nouvelle-AQUItaine (France)
NCT ID: NCT06493955
Last Updated: 2025-02-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
NA
308 participants
INTERVENTIONAL
2025-09-30
2028-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The investigators would therefore like to assess whether extending the existing "Passerelle program" by 6 months, with one session every 15 days, is effective in maintaining the volume of physical activity 12 months after the end of the intervention.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Adapted Physical Activity Study
NCT03337412
Persistence of Physical Activity in People With Type 2 Diabetes Over Time.
NCT05661799
Active Communities - Adherence to Physical Activity
NCT05493345
Consultations in Adapted Physical Activity on Behaviours in Physical Exercise by Type 2 Diabetics
NCT00403741
Diabetes Prevention in Clinical Practice.
NCT01834378
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The management of type 2 diabetic patients aims to reduce morbidity and mortality through glycemic control. The latest French recommendations for the management of diabetic patients date from 2014, and encourage doctors to monitor their patients every three months to ensure compliance, look for risk factors and comorbidities (hypertension, smoking and alcohol consumption), measure blood pressure, weight and calculate BMI. HbA1c tests should be carried out between two and four times a year. The first recommended hypoglycemic treatment is based on physical activity and diet.
More recent recommendations from the American Diabetes Association (ADA) in 2022 encourage physicians to manage patients using a multifactorial approach. First-line management involves lifestyle changes, promoting healthier behaviors around diet, physical activity promotion, substance use such as smoking, weight loss and sleep quality.
Sport-health networks such as the PEPS network in the Nouvelle-Aquitaine region (Prescription d'Exercice Physique pour la Santé - Prescription of Physical Exercise for Health) make it easier for patients to be referred to a suitable structure for supervised exercise.
Investigators would like to know whether extending this program with spaced sessions can encourage patients to change their behavior over the long term. Spacing out the sessions should enable a smoother transition to independent or associative practice.
The research question is as follows: What is the effectiveness of a one-year Passerelle program in maintaining the volume of physical activity in T2DM patients in the Nouvelle-Aquitaine region?
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
SUPPORTIVE_CARE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
experimental arm
Patients with type 2 diabetes included in the adapted physical activity arm for 12 months
Adapted physical activity for 12 months
6 additional months of adapted physical activity after the 6 first months
control arm
Type 2 diabetes patients with standard prescription for adapted physical activity (6 months)
Adapted physical activity for 6 months
standard 6-month prescription for adapted physical activity
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Adapted physical activity for 12 months
6 additional months of adapted physical activity after the 6 first months
Adapted physical activity for 6 months
standard 6-month prescription for adapted physical activity
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patient aged 18 or over
* Patient with a Marshall score ≤ 3
* Patient residing in the Nouvelle-Aquitaine region
* Patient eligible for the "Passerelle" program
* Patient willing to participate
* Patient agreeing to take part in the study and having signed an informed consent form
* Person affiliated or benefiting from a social security scheme.
Exclusion Criteria
* Cardiovascular: unstable angina, stress angina, malignant hypertension, recent myocardial infarction, unstabilized heart disease
* Pulmonary: uncontrolled asthma, COPD exacerbation
* Endocrine: diabetes with HbA1c \> 9%, plantar perforator disease
* Pregnant patient
* Diabetic patient with contraindication to APA prescription
* Patient under court protection
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Bordeaux
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Cabinet Médical Bergerac
Bergerac, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CHUBX 2023/47
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.